Prime Medicine doses first patient in Phase 1/2 trial of PM577a for H1069Q-mutated Wilson disease

Bitget2026/10/05 12:13

Prime Medicine dosed the first patient in a global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson disease. The first-in-human study aims to assess safety and early signs of benefit from a one-time gene-editing treatment. Initial clinical data are expected in 2027, with results to be presented in the future. The FDA granted Rare Pediatric Disease designation to PM577, supporting the program’s regulatory strategy in a childhood-onset condition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839217) on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal

UToday•2026/10/11 10:27

Viral Altcoin Defies Market Slumber With 53% Surge, BTC Calms at $83K: Weekend Watch

Cryptopotato•2026/10/11 10:21

Global Bank Stocks Sink as Bond Losses Top $326 Billion: Is Another SVB Coming?

BeInCrypto•2026/10/11 10:06

Exclusive Report - Sources Say INWIT Investors Are Raising Funds for a Possible Privatization Deal

路透社•2026/10/11 08:51